Rocket Pharmaceuticals Dirección

Dirección controles de criterios 2/4

El CEO de Rocket Pharmaceuticals es Gaurav Shah , nombrado en Jan 2018, tiene una permanencia de 6.92 años. compensación anual total es $8.01M, compuesta por 7.8% salario y 92.2% primas, incluidas acciones y opciones de la empresa. posee directamente un 1.22% de las acciones de la empresa, por valor de €15.14M. La antigüedad media del equipo directivo y de la junta directiva es de 3.3 años y 6.9 años, respectivamente.

Información clave

Gaurav Shah

Chief Executive Officer (CEO)

US$8.0m

Compensación total

Porcentaje del salario del CEO	7.8%
Permanencia del CEO	6.9yrs
Participación del CEO	1.2%
Permanencia media de la dirección	3.3yrs
Promedio de permanencia en la Junta Directiva	6.9yrs

Actualizaciones recientes de la dirección

Recent updates

Análisis de compensación del CEO

¿Cómo ha cambiado la remuneración de Gaurav Shah en comparación con los beneficios de Rocket Pharmaceuticals?
Fecha	Compensación total	Salario	Ingresos de la empresa
Sep 30 2024	n/a	n/a	-US$258m
Jun 30 2024	n/a	n/a	-US$253m
Mar 31 2024	n/a	n/a	-US$249m
Dec 31 2023	US$8m	US$625k	-US$246m
Sep 30 2023	n/a	n/a	-US$253m
Jun 30 2023	n/a	n/a	-US$249m
Mar 31 2023	n/a	n/a	-US$237m
Dec 31 2022	US$7m	US$598k	-US$222m
Sep 30 2022	n/a	n/a	-US$199m
Jun 30 2022	n/a	n/a	-US$192m
Mar 31 2022	n/a	n/a	-US$172m
Dec 31 2021	US$8m	US$590k	-US$169m
Sep 30 2021	n/a	n/a	-US$186m
Jun 30 2021	n/a	n/a	-US$165m
Mar 31 2021	n/a	n/a	-US$155m
Dec 31 2020	US$7m	US$540k	-US$140m
Sep 30 2020	n/a	n/a	-US$99m
Jun 30 2020	n/a	n/a	-US$89m
Mar 31 2020	n/a	n/a	-US$82m
Dec 31 2019	US$4m	US$480k	-US$77m
Sep 30 2019	n/a	n/a	-US$85m
Jun 30 2019	n/a	n/a	-US$82m
Mar 31 2019	n/a	n/a	-US$79m
Dec 31 2018	US$6m	US$414k	-US$75m

Compensación vs. Mercado: La compensación total de Gaurav($USD8.01M) está por encima de la media de empresas de tamaño similar en el mercado German ($USD1.67M).

Compensación vs. Ingresos: La compensación de Gaurav ha aumentado mientras la empresa no es rentable.

CEO

Gaurav Shah (49 yo)

6.9yrs

Permanencia

US$8,013,553

Compensación

Dr. Gaurav D. Shah, M.D., has been an Independent Director at Talaris Therapeutics, Inc. since December 2020. He serves as the Chief Executive Officer and Director of Rocket Pharmaceuticals, Ltd since Janu...

Equipo directivo

Nombre	Posición	Permanencia	Compensación	Propiedad
Gaurav Shah	CEO & Director	6.9yrs	US$8.01m	1.22% € 15.1m
Kinnari Patel	Head of R&D	6.9yrs	US$4.85m	0.44% € 5.4m
Mayo Pujols	Chief Technical Officer	2.4yrs	US$4.38m	0.062% € 770.0k
Jonathan Schwartz	Chief Medical & Gene Therapy Officer	6.9yrs	US$3.16m	0.11% € 1.3m
Aaron Ondrey	Chief Financial Officer	less than a year	sin datos	sin datos
Martin Wilson	General Counsel	3.1yrs	US$1.56m	0.070% € 864.4k
Kevin Giordano	Director of Corporate Communications	no data	sin datos	sin datos
Isabel Carmona	Chief People Officer	3.3yrs	sin datos	sin datos
Gayatri Rao	Senior VP of Clinical Safety & Chief Regulatory Officer	4.7yrs	sin datos	sin datos
Raj Prabhakar	Chief Business Officer	no data	US$2.82m	0% € 0
Carlos Martin	Chief Commercial Operations & Revenue Officer	less than a year	sin datos	sin datos

3.3yrs

Permanencia media

49yo

Promedio de edad

Equipo directivo experimentado: El equipo directivo de 9IP1 se considera experimentado (3.3 años antigüedad media).

Miembros de la Junta

Nombre	Posición	Permanencia	Compensación	Propiedad
Gaurav Shah	CEO & Director	6.9yrs	US$8.01m	1.22% € 15.1m
David Southwell	Independent Director	10.3yrs	US$399.99k	0.13% € 1.6m
Pedro Granadillo	Independent Director	6.9yrs	US$429.98k	0% € 0
Carsten Boess	Independent Director	8.9yrs	US$427.49k	0% € 0
Mikael Dolsten	Independent Director	less than a year	sin datos	sin datos
Roderick Tze Wong	Chairman of the Board	6.9yrs	US$409.99k	0.059% € 729.1k
Naveen Yalamanchi	Independent Director	6.9yrs	US$417.49k	0.13% € 1.6m
Fady Malik	Independent Non-Executive Director	2.8yrs	US$399.99k	0% € 0
Elisabeth Bjork	Independent Director	4.7yrs	US$409.99k	0% € 0
Gotham Makker	Director	6.9yrs	US$399.99k	0.22% € 2.7m
Robert Woods	Independent Non- Executive Director	less than a year	US$568.70k	sin datos

6.9yrs

Permanencia media

58yo

Promedio de edad

Junta con experiencia: La junta directiva de 9IP1 se considera experimentada (6.9 años de antigüedad promedio).

Rocket Pharmaceuticals Dirección

Dirección controles de criterios 2/4

Información clave

Actualizaciones recientes de la dirección

Rocket Pharmaceuticals, Inc. Appoints Mikael Dolsten to the Board

Rocket Pharmaceuticals, Inc., Annual General Meeting, Jun 13, 2024

Insider recently sold €284k worth of stock

Rocket Pharmaceuticals, Inc. Announces Executive Appointments

CEO & Director recently sold €561k worth of stock

Rocket Pharmaceuticals, Inc. Appoints R. Keith Woods as Independent, Non-Executive Director

Recent updates

New minor risk - Profitability

Rocket Pharmaceuticals, Inc. Announces Completion of Enrollment in Phase 2 Pivotal Trial of RP-A501 for the Treatment of Danon Disease

Rocket Pharmaceuticals, Inc. Appoints Mikael Dolsten to the Board

Rocket Pharmaceuticals, Inc. Provides Regulatory Update on KRESLADI™ (marnetegragene autotemcel; marne-cel)

Rocket Pharmaceuticals Presents Positive Data from Lv Hematology Portfolio At the 27Th Annual Meeting of the American Society of Gene and Cell Therapy (Asgct)

New minor risk - Profitability

Rocket Pharmaceuticals, Inc., Annual General Meeting, Jun 13, 2024

Insider recently sold €284k worth of stock

Rocket Pharmaceuticals, Inc. Announces European Medicines Agency Acceptance of RP-L102 Marketing Authorization Application for the Treatment of Fanconi Anemia

Rocket Pharmaceuticals, Inc. Announces Executive Appointments

No longer forecast to breakeven

CEO & Director recently sold €561k worth of stock

Rocket Pharmaceuticals, Inc. Announces Update on Fda Review Timeline of Kresladi™ (Marnetegragene Autotemcel) for the Treatment of Severe Leukocyte Adhesion Deficiency-I (Lad-I)

New minor risk - Profitability

Forecast to breakeven in 2026

Rocket Pharmaceuticals, Inc. Appoints R. Keith Woods as Independent, Non-Executive Director

New major risk - Revenue and earnings growth

New minor risk - Profitability

Rocket Pharmaceuticals, Inc. Announces Fda Acceptance of Biologics License Application with Priority Review for Rp-L201 (Marnetegragene Autotemcel) for the Treatment of Severe Leukocyte Adhesion Deficiency-I (Lad-I)

Rocket Pharmaceuticals Receives European Medicines Agency (Ema) Priority Medicines (Prime) Designation for RP-A501 Gene Therapy for Danon Disease

CEO & Director recently sold €81k worth of stock

Rocket Pharmaceuticals, Inc. Announces FDA Clearance of IND for Clinical Trial of RP-A601 for PKP2 Arrhythmogenic Cardiomyopathy (ACM)

Insufficient new directors

Insider recently sold €64k worth of stock

Rocket Pharmaceuticals Receives FDA Regenerative Medicine Advanced Therapy (RMAT) Designation for RP-A501 Gene Therapy for Danon Disease

Rocket Pharmaceuticals Expands Cardiac Gene Therapy Portfolio with Addition of RP-A601 for PKP2-ACM

Rocket Pharmaceuticals, Inc. Provides Update on Anticipated Registration Path for RP-A501 in Danon Disease Following End-Of-Phase 1 FDA Meeting

Rocket Pharmaceuticals, Inc. (NasdaqGM:RCKT) completed the acquisition of Renovacor, Inc. (NYSEAM:RCOR) from RTW Investments, LP, Chardan Investments 2, LLC and others,

Rocket Pharmaceuticals, Inc. Announces Presentations Highlighting Lentiviral Gene Therapies at the 29th Annual Congress of the European Society of Gene & Cell Therapy (ESGCT)

Rocket Pharmaceuticals Announces Positive Updates from Phase 1 Clinical Trial for RP-A501 in Danon Disease at the Heart Failure Society of America (HFSA) Annual Scientific Meeting 2022

Rocket Pharmaceuticals, Inc. (NasdaqGM:RCKT) entered into a definitive agreement to acquire Renovacor, Inc. (NYSEAM:RCOR) from RTW Investments, LP and others for $46.7 million.

Rocket Pharmaceuticals, Inc. (NasdaqGM:RCKT) entered into a definitive agreement to acquire Renovacor, Inc. (NYSEAM:RCOR) from RTW Investments, LP and others for $46.7 million.

Rocket Pharmaceuticals, Inc. Appoints Mayo Pujols as Chief Technical Officer and Executive Vice President

Rocket Pharmaceuticals Presents Positive Top-Line Data from Severe Leukocyte Adhesion Deficiency-I Program At the 25Th Annual Meeting of the American Society of Gene and Cell Therapy (Asgct)

Rocket Pharmaceuticals, Inc. Presents Positive Clinical Data from Danon Disease, Fanconi Anemia and Pyruvate Kinase Deficiency Programs at the 25th Annual Meeting of the American Society of Gene and Cell Therapy (ASGCT)

Rocket Pharmaceuticals, Inc., Annual General Meeting, Jun 13, 2022

Rocket Pharmaceuticals Appoints Fady Malik to Board of Directors

Rocket Pharmaceuticals Appoints Jessie Yeung as Vice President of Investor Relations and Corporate Finance

CEO & Director recently bought €334k worth of stock

Rocket Pharmaceuticals Presents Positive Clinical Data from Company’s Lentiviral Gene Therapies for Treatment of Fanconi Anemia, LAD-I and PKD at the 63rd American Society of Hematology (ASH) Annual Meeting

Rocket Pharmaceuticals, Inc. Presents Positive Clinical Data from Fanconi Anemia, Leukocyte Adhesion Deficiency-I, and Pyruvate Kinase Deficiency Programs at 24Th Annual Meeting of the American Society of Gene and Cell Therapy

Rocket Pharmaceuticals Receives FDA Regenerative Medicine Advanced Therapy Designation for RP-L201 Gene Therapy for Leukocyte Adhesion Deficiency-I

New 90-day high: €52.50

Rocket Pharmaceuticals, Inc. Announces Executive Appointments

Rocket Pharmaceuticals, Inc. has completed a Follow-on Equity Offering in the amount of $260.000048 million.

Rocket Pharmaceuticals Presents Positive Clinical Data from its Fanconi Anemia and Leukocyte Adhesion Deficiency-I Programs at the 62nd American Society of Hematology Annual Meeting

New 90-day high: €50.00

Rocket Pharmaceuticals Announces Positive Preliminary Clinical Data from Phase 1 Trial of RP-L301 for the Treatment of Pyruvate Kinase Deficiency at the 62nd American Society of Hematology Annual Meeting

New 90-day high: €28.40

Inotek Pharmaceuticals Corporation Receives Funding from the California Institute for Regenerative Medicine for Phase 1 Clinical Trial of RP-L401 for Infantile Malignant Osteopetrosis

Rocket Pharmaceuticals, Inc. Presents Positive LAD-L Clinical Update and Comprehensive IMO Preclinical Review At the European Society for Immunodeficiencies 2020 Meeting

New 90-day high: €25.00

New 90-day high - €22.40

Rocket Pharmaceuticals, Inc.(NasdaqGM:RCKT) dropped from Russell Microcap Index

Análisis de compensación del CEO

CEO

Permanencia

Compensación

Equipo directivo

Permanencia media

Promedio de edad

Miembros de la Junta

Permanencia media

Promedio de edad